"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in one clinical trial of a drug cannot be directly compared with the rates in the clinical trials of the same or another drug and may not reflect the rates observed in practice.
The data described below reflect exposure to Besivance® in approximately 1,000 patients between 1 and 98 years old with clinical signs and symptoms of bacterial conjunctivitis.
The most frequently reported ocular adverse reaction was conjunctival redness, reported in approximately 2% of patients.
Other adverse reactions reported in patients receiving Besivance® occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
Read the Besivance (besifloxacin ophthalmic suspension) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 10/26/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Besivance Information
Besivance - User Reviews
Besivance User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.